Search results for "vulvar cancer"

showing 10 items of 16 documents

Endoscopic near infrared and indocyanine green to verify the viability of the subcutaneous flap for vulvar cancer.

2019

Abstract Introduction Vulvar cancer often requires radical vulvectomy with subsequent vulvar flap. Approximately in 20–60% of cases, there are post-operative complications ranging from infection to flap necrosis that often require reoperation. Several methods have been described to verify the vitality of the flap, but these are often expensive and require specific machinery that is not generally present in a gynecological clinic. In this case report, we present a viability verification of V Y fasciocutaneous advancement flap for vulvar reconstruction by Endoscopic Near-Infrared and Indocyanine Green. Methodology The patient was a 67-year-old woman with FIGO IB ≤ 4 cm squamous cell vulvar ca…

0301 basic medicineIndocyanine Greenmedicine.medical_specialtySurgical Flaps03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicineHumansAgedSpectroscopy Near-InfraredVulvar Neoplasmsbusiness.industryWound dehiscenceObstetrics and GynecologyInguinal lymphadenopathyVulvar cancerPlastic Surgery Proceduresmedicine.diseaseLateral marginSurgery030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisRadical VulvectomyCarcinoma Squamous CellLymph Node ExcisionVulvectomyFemaleFlap necrosismedicine.symptombusinessIndocyanine greenSurgical site infectionGynecologic oncology
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct

Reconstructive surgery following resection of primary vulvar cancers.

2005

Objective. This study describes the surgical treatment and follow-up of 213 patients with primary vulvar cancer; particular attention is given to reconstructive surgical procedures. Methods. The clinical and pathological parameters of the patients were recorded according to standardized procedures, and the data concerning type of operation, surgical reconstruction and postoperative course of disease (recurrence-free and overall survival) were analyzed. Results. In about one-third of the cases, plastic surgery reconstruction involving skin-flaps was performed. In the present group of patients, plastic surgery procedures led to an elevated degree of operability as well as to more satisfactory…

AdultReconstructive surgerymedicine.medical_specialtySurgical FlapsResectionVulvamedicineHumansSurgical FlapsPathologicalAgedVulvar neoplasmAged 80 and overintegumentary systemVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle AgedPlastic Surgery Proceduresmedicine.diseaseSurgeryPlastic surgerymedicine.anatomical_structureOncologyFemalebusinessFollow-Up StudiesGynecologic oncology
researchProduct

A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis

2003

Abstract Objective . The interleukin-1 (IL-1) family, that is, IL-1α and β and the IL-1 receptor antagonist (IL-1RA), is known to modulate various tumorgenic and tumorcidal effects in humans. Its biological function in squamous cell carcinogenesis of various anatomical sites has been stressed. Although various studies showed a certain association between genes encoding the IL-1 family and human malignancies, no data with respect to vulvar cancer have been published to date. Methods . We ascertained four polymorphisms of the IL-1α gene ( IL1A C[−889]T), the IL-1β gene ( IL1B promoter C[-511]T and IL1B exon 5 position +3953), and the IL-1RA gene ( IL1RN intron 2) in 68 patients with surgicall…

AdultSialoglycoproteinsBiologyBioinformaticsmedicine.disease_causePolymerase Chain ReactionExonGene clustermedicineHumansPromoter Regions GeneticAllelesAgedNeoplasm StagingAged 80 and overVulvar neoplasmPolymorphism GeneticVulvar NeoplasmsObstetrics and GynecologyInterleukinExonsMiddle AgedVulvar cancermedicine.diseaseInterleukin 1 Receptor Antagonist ProteinCell Transformation NeoplasticInterleukin 1 receptor antagonistOncologyIL1AMultigene FamilyCarcinoma Squamous CellCancer researchFemaleCarcinogenesisInterleukin-1Gynecologic Oncology
researchProduct

Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study

2020

ObjectiveObesity is associated with worse survival and an increased risk of relapse in several malignancies. The influence of obesity on vulvar cancer recurrence has not been previously described. The primary objective of this study was to evaluate the association between obesity and tumor recurrence in patients with vulvar cancer.MethodsThis is an analysis of the AGO-CaRE-1 study. Patients diagnosed with squamous cell vulvar cancer (stage IB and higher), treated in 29 cancer centers between January 1998 and December 2008, were registered in a centralized database. The cohort was divided into two gropus depending on the body mass index (BMI) (<30 vs ≥30 kg/m²). Descriptive statistics, su…

Adultmedicine.medical_specialtyBody Mass IndexYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeGermanyInternal medicinemedicineHumansObesityAgedNeoplasm StagingAged 80 and over030219 obstetrics & reproductive medicineVulvar Neoplasmsbusiness.industryObstetrics and GynecologyCancerMiddle AgedVulvar cancermedicine.diseaseObesityIncreased riskOncologyTime to recurrence030220 oncology & carcinogenesisCohortCarcinoma Squamous CellFemaleNeoplasm Recurrence LocalbusinessBody mass indexInternational Journal of Gynecologic Cancer
researchProduct

Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study

2018

Objectives This retrospective, multicentric study investigates quality-of-life issues and emotional distress in gynecological cancer survivors submitted to pelvic exenteration (PE). Methods The Global Health Status scale of European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30; the EORTC QLQ-CX24 (CX24), and EORTC QLQ-OV28 questionnaires were administered at least 12 months from surgery only in women with no evidence of further recurrence after PE. Statistical analysis was performed by the analysis of variance (for repeated measures. Results Ninety-six subjects affected by gynecological malignancies receiving PE were enrolled in the s…

Adultmedicine.medical_specialtyConstipationGenital Neoplasms Femalemedicine.medical_treatmentHealth StatusUrinary Diversion03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesmedicineBody ImageHumansAgedRetrospective StudiesGynecology030219 obstetrics & reproductive medicinePelvic exenterationbusiness.industryHazard ratioColostomyRepeated measures designObstetrics and GynecologyRetrospective cohort studyQuality of life Pelvic exenteration Gynecological cancerVulvar cancerMiddle Agedmedicine.diseasePelvic ExenterationOncology030220 oncology & carcinogenesisGynecological cancerQuality of LifeFemalemedicine.symptombusiness
researchProduct

Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.

2013

ObjectiveOur study purpose was to evaluate morbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies.MethodsWe identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso.ResultsThe median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performe…

Adultmedicine.medical_specialtyGenital Neoplasms Femalemedicine.medical_treatmentYoung AdultRetrospective StudieGermanymedicineHumansPostoperative PeriodMortalityAgedRetrospective StudiesAged 80 and overCervical cancerVaginal cancerHysterectomyGynecological malignanciePelvic exenterationbusiness.industryEndometrial cancerMortality rateGynecological malignanciesObstetrics and GynecologyPerioperativeMiddle AgedVulvar cancermedicine.diseaseSurvival AnalysisPelvic ExenterationSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncologyFemaleSurvival AnalysiMorbidityMorbidity pelvic exenteration gynecological malignanciesbusinessHuman
researchProduct

Oxygenation Status of Gynecologic Tumors: What is the Optimal Hemoglobin Level?

2002

Tumor hypoxia has been linked to the development of treatment resistance, tumor progression, and poor prognosis. Since anemia is a major causative factor for the development of hypoxia, the association between blood hemoglobin concentration (cHb) and tumor oxygenation was examined in this study.Pretreatment O(2) tension (pO(2)) measurements were performed in 59 primary carcinomas of the uterine cervix in which a stringent histopathologic examination of the electrode tracks was mandatory in order to exclude measurements in necrotic, stromal or normal cervical tissue. In addition, pO(2) readings in twelve primary cancers and 17 local recurrences of vulvar cancers were included in this study. …

Adultmedicine.medical_specialtyPathologyAnemiaUterine Cervical NeoplasmsCervix UteriGastroenterologyVulvaOxygen ConsumptionInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm StagingVulvar NeoplasmsTumor hypoxiabusiness.industryMiddle AgedTumor OxygenationVulvar cancerHypoxia (medical)Prognosismedicine.diseaseCell HypoxiaTreatment OutcomeOncologyTumor progressionCarcinoma Squamous CellHemoglobinometryFemaleHemoglobinemiamedicine.symptombusinessStrahlentherapie und Onkologie
researchProduct

Vulvar and Vaginal Cancers

2021

Vulvar cancer and vaginal cancer are relatively rare tumors, typically affecting elder women, although they still represent the fourth and fifth, respectively, most common cancers in the gynecologic oncology field. Treatment of the early stages includes surgery and radiotherapy (external beam radiotherapy and brachytherapy). The sentinel lymph node sampling procedure is becoming the new standard of care in vulvar cancer. Chemotherapy has a role in combination with radiotherapy for the locoregional management or as palliative therapy for stage IV patients.

ChemotherapyVaginal cancermedicine.medical_specialtybusiness.industrymedicine.medical_treatmentBrachytherapySentinel lymph nodeGynecologic oncologyVulvar cancermedicine.diseaseRadiation therapymedicineExternal beam radiotherapyRadiologybusiness
researchProduct

345 Comparison of cisplatin and mitomycin/5-FU as radiosensitizers in the treatment of vulvar cancer – results of a single institutional cohort study

2021

Introduction/Background* Treatment of vulvar cancer contains surgery if applicable and often primary or neo-/adjuvant chemoradiation. Cisplatin and Mitomycin/5-FU are widely used radiosensitizers in vulvar cancer, although evidence is limited. We retrospectively investigated both radiosensitizers for outcome and toxicity. Methodology We screened the archive for patients treated with chemoradiation for pathologically-confirmed squamous cell cancer of the vulva between 01/2010 – 02/2021 at our institution. The impact of both radiosensitizers on prognosis was compared using Kaplan-Meier method and Cox-Regression analysis. Result(s)* 127 patients with vulvar cancer were screened. 24 patients re…

Cisplatinmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentVulvar cancermedicine.diseaseGastroenterologyVulvamedicine.anatomical_structureInternal medicineToxicityMedicineStage (cooking)businessAdverse effectAdjuvantmedicine.drugCohort studyVaginal and vulvar cancer
researchProduct